203 related articles for article (PubMed ID: 37437037)
21. ScRNA-seq revealed targeting regulator of G protein signaling 1 to mediate regulatory T cells in Hepatocellular carcinoma.
Zou L; Liu K; Shi Y; Li G; Li H; Zhao C
Cancer Biomark; 2023; 36(4):299-311. PubMed ID: 36938729
[TBL] [Abstract][Full Text] [Related]
22. Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes.
Gil-Varea E; Spataro N; Villar LM; Tejeda-Velarde A; Midaglia L; Matesanz F; Malhotra S; Eixarch H; Patsopoulos N; Fernández Ó; Oliver-Martos B; Saiz A; Llufriu S; Ramió-Torrentà L; Quintana E; Izquierdo G; Alcina A; Bosch E; Navarro A; Montalban X; Comabella M
Hum Mutat; 2020 Jul; 41(7):1308-1320. PubMed ID: 32196808
[TBL] [Abstract][Full Text] [Related]
23. Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer.
Lazaridis G; Lambaki S; Karayannopoulou G; Eleftheraki AG; Papaspirou I; Bobos M; Efstratiou I; Pentheroudakis G; Zamboglou N; Fountzilas G
Strahlenther Onkol; 2014 Jul; 190(7):636-8, 640-5. PubMed ID: 24658605
[TBL] [Abstract][Full Text] [Related]
24. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma.
Lee N; Lee H; Moon SY; Sohn JY; Hwang SM; Yoon OJ; Youn HS; Eom HS; Kong SY
Ann Lab Med; 2015 Nov; 35(6):563-9. PubMed ID: 26354343
[TBL] [Abstract][Full Text] [Related]
25. Meta-Analysis on Associations of RGS1 and IL12A Polymorphisms with Celiac Disease Risk.
Guo CC; Wang M; Cao FD; Huang WH; Xiao D; Ye XG; Ou ML; Zhang N; Zhang BH; Liu Y; Yang G; Jing CX
Int J Mol Sci; 2016 Mar; 17(4):457. PubMed ID: 27043536
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival.
Cetin M; Buyukberber S; Demir M; Sari I; Sari I; Deniz K; Eser B; Altuntas F; Camci C; Oztürk A; Turgut B; Vural O; Unal A
Am J Hematol; 2005 Nov; 80(3):169-73. PubMed ID: 16247750
[TBL] [Abstract][Full Text] [Related]
27. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E
J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
[TBL] [Abstract][Full Text] [Related]
29. The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma.
Li J; Zhu J; Cao B; Mao X
Curr Pharm Des; 2014; 20(1):125-35. PubMed ID: 24001224
[TBL] [Abstract][Full Text] [Related]
30. The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.
Zhang X; Wu Y; Sun X; Cui Q; Bai X; Dong G; Gao Z; Wang Y; Gao C; Sun S; Ji N; Liu Y
BMC Cancer; 2022 Feb; 22(1):190. PubMed ID: 35184749
[TBL] [Abstract][Full Text] [Related]
31. RGS1 and related genes as potential targets for immunotherapy in cervical cancer: computational biology and experimental validation.
Zhang S; Wang H; Liu J; Tao T; Zeng Z; Wang M
J Transl Med; 2022 Jul; 20(1):334. PubMed ID: 35879796
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma.
Leal P; García P; Sandoval A; Letelier P; Brebi P; Ili C; Álvarez H; Tapia O; Roa JC
Arch Pathol Lab Med; 2013 Apr; 137(4):552-7. PubMed ID: 23544944
[TBL] [Abstract][Full Text] [Related]
33. Prognostic role of TNF alpha, LT alpha, MDR1 and codon 72 Tp53 gene polymorphisms on multiple myeloma Egyptian patients.
Hegazi HM; Elghonemy MS; El-Baiomy MA; Soliman EA; Abdel-Hady EK
Leuk Res; 2022 Jun; 117():106854. PubMed ID: 35594781
[TBL] [Abstract][Full Text] [Related]
34. Cyclin D1 amplification in multiple myeloma is associated with multidrug resistance expression.
Sewify EM; Afifi OA; Mosad E; Zaki AH; El Gammal SA
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):215-22. PubMed ID: 24468132
[TBL] [Abstract][Full Text] [Related]
35. Correlation of the AKT/mTOR signaling pathway with the clinicopathological features and prognosis of nasopharyngeal carcinoma.
Wang Y; Sun J; Yao N
Eur J Histochem; 2021 Nov; 65(4):. PubMed ID: 34783234
[TBL] [Abstract][Full Text] [Related]
36. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
37. Uniform expression of Notch1, suppressor of B-cell-specific gene expression, in plasmablastic lymphoma.
Seegmiller AC; Wang HY; Hladik C; Chen W
Arch Pathol Lab Med; 2011 Jun; 135(6):770-5. PubMed ID: 21631271
[TBL] [Abstract][Full Text] [Related]
38. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
Atanackovic D; Luetkens T; Hildebrandt Y; Arfsten J; Bartels K; Horn C; Stahl T; Cao Y; Zander AR; Bokemeyer C; Kröger N
Clin Cancer Res; 2009 Feb; 15(4):1343-52. PubMed ID: 19190130
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Significance of mTOR and PTEN in Patients with Esophageal Squamous Cell Carcinoma.
Lu J; Pan Y; Xia X; Gu Y; Lei Y
Biomed Res Int; 2015; 2015():417210. PubMed ID: 26357655
[TBL] [Abstract][Full Text] [Related]
40. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.
Kashani-Sabet M; Nosrati M; Miller JR; Sagebiel RW; Leong SPL; Lesniak A; Tong S; Lee SJ; Kirkwood JM
Clin Cancer Res; 2017 Nov; 23(22):6888-6892. PubMed ID: 28790109
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
